Testing effectiveness (Phase 2)Looking for participantsNCT06534060What this trial is testingMB-105 in Patients With CD5 Positive T-cell LymphomaWho this might be right forLymphoma, T-Cell March Biosciences Inc 46
Early research (Phase 1)Study completedNCT01902225What this trial is testingPhase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell LymphomaWho this might be right forLymphomaT-Cell LymphomaCutaneous Lymphoma Weiyun Ai 24
Testing effectiveness (Phase 2)UnknownNCT04626908What this trial is testingClinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin LymphomaWho this might be right forRelapsed and RefractoryLymphoid Hematological Malignancies He Huang 18
Testing effectiveness (Phase 2)Study completedNCT00052520What this trial is testingBiological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell TransplantationWho this might be right forAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)+20 more Fred Hutchinson Cancer Center 37
Early research (Phase 1)Active Not RecruitingNCT05665062What this trial is testingAutologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic MalignanciesWho this might be right forCLL/SLLNHLMantle Cell Lymphoma+4 more Synthekine 36
Testing effectiveness (Phase 2)Study completedNCT03373071What this trial is testingAnti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHLWho this might be right forCD19-ALLCD19-LNH Bambino Gesù Hospital and Research Institute 29
Testing effectiveness (Phase 2)Study completedNCT00684619What this trial is testing506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL)Who this might be right forT-ALL, T-NHL (Lymphoblastic) Goethe University 120
Early research (Phase 1)Study completedNCT00005634What this trial is testingSuberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous TherapyWho this might be right forLeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+3 more Memorial Sloan Kettering Cancer Center
Early research (Phase 1)Ended earlyNCT03103971What this trial is testingHuJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic LeukemiaWho this might be right forRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma+14 more Fred Hutchinson Cancer Center 55
Early research (Phase 1)Ended earlyNCT01088763What this trial is testingGamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell LeukemiaWho this might be right forChildhood Atypical Teratoid/Rhabdoid TumorChildhood Central Nervous System ChoriocarcinomaChildhood Central Nervous System Germinoma+43 more National Cancer Institute (NCI) 129
Early research (Phase 1)Study completedNCT00114257What this trial is testingDecitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative DisordersWho this might be right forChronic Myeloproliferative DisordersLeukemiaMyelodysplastic Syndromes+1 more National Cancer Institute (NCI) 36
Testing effectiveness (Phase 2)Looking for participantsNCT04484012What this trial is testingModified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell LymphomaWho this might be right forRecurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma City of Hope Medical Center 36
Testing effectiveness (Phase 2)UnknownNCT05429905What this trial is testingDual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage LeukaemiaWho this might be right forLymphoblastic LeukemiaLymphoblastic Leukemia, Acute, ChildhoodLymphoblastic Leukemia in Children+2 more KK Women's and Children's Hospital 48
Testing effectiveness (Phase 2)Looking for participantsNCT06213636What this trial is testingFourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).Who this might be right forAcute Lymphoblastic Leukemia, Adult B-CellAcute Lymphoblastic Leukemia, in RelapseNon-Hodgkin Lymphoma, B-cell+4 more Essen Biotech 75
Testing effectiveness (Phase 2)WithdrawnNCT01101412What this trial is testingAntimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With MalignanciesWho this might be right forChronic Myeloproliferative DisordersInfectionLeukemia+6 more M.D. Anderson Cancer Center
Early research (Phase 1)Looking for participantsNCT06914037What this trial is testingA Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological MalignanciesWho this might be right forPeripheral T-cell LymphomaCutaneous T-cell Lymphoma (CTCL)NHL (Non-Hodgkin Lymphoma) Tianjin Medical University Cancer Institute and Hospital 24
Testing effectiveness (Phase 2)Study completedNCT00053131What this trial is testingCombination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaWho this might be right forLeukemia Roswell Park Cancer Institute
Testing effectiveness (Phase 2)Study completedNCT02588651What this trial is testingA Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)Who this might be right forT-cell LymphomaAngioimmunoblastic T-cell LymphomaHepato-splenic T-cell Lymphoma+3 more Deepa Jagadeesh 23
Early research (Phase 1)Study completedNCT00107354What this trial is testingCellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell TransplantWho this might be right forLeukemiaMyelodysplastic Syndromes Fred Hutchinson Cancer Center
Very early researchLooking for participantsNCT06976437What this trial is testingA Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant TumorsWho this might be right forB Cell LymphomaMultiple Myeloma YANRU WANG 21